3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
95
Breast Neoplasms
12
Neoplasms
7
Leiomyoma
4
Rare Diseases
2
Polycystic Ovary Syndrome
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urogenital Neoplasms
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Skin Neoplasms
1
Skin Diseases
1
Sexual Dysfunction, Physiological
1
Respiratory Tract Diseases
1
Prostatic Diseases
1
Primary Dysautonomias
1
Premenopausal Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Compliance
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms, Glandular and Epithelial
1
Myofibroma
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphatic Metastasis
1
Lower Urinary Tract Symptoms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Interventions
Everolimus
5
Alpelisib
4
berzosertib
3
PX-866
3
Letrozole
3
Fulvestrant
3
Cetuximab
3
Topotecan
2
NVP-BKM120
2
tipifarnib
1
sotorasib
1
serabelisib
1
ribociclib
1
pembrolizumab
1
parsaclisib
1
palbociclib
1
gedatolisib
1
duvelisib
1
ceralasertib
1
capivasertib
1
binimetinib
1
Trimetazidine
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hereditary Sensory and Autonomic Neuropathies
×
Leuprolide
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts